Targeting AMPK: A new therapeutic opportunity in breast cancer

被引：136

作者：

Hadad, Sirwan M. ^{[1
]}

Fleming, Stewart

Thompson, Alastair M.

机构：

[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2008年 / 67卷 / 01期

关键词：

cancer; breast cancer; mTOR; AMPK; TSC; Akt; rapamycin; metformin;

D O I：

10.1016/j.critrevonc.2008.01.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evidence targeting this pathway directly or through activation of AMP-activated protein kinase (AMPK) as an additional therapeutic opportunity for intervention in breast cancer. Methods: Relevant articles were identified through computerised searches of Medline and Pubmed. Secondary articles were identified from the reference lists of key papers and by hand searching. Results and conclusion: The current consensus to target the AMPK/mTOR pathway in breast cancer is based on in vitro and epidemiological evidences. A low incidence of cancer in diabetic patients on metformin has been explained in vitro by the drug's anti-proliferative effect through activation of AMPK. There is a need to explore the anticancer effects of metformin and the potential to develop the therapeutic avenues offered by targeting the AMPK/mTOR pathway. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 7

页数：7

共 86 条

[1] LKB1-dependent signaling pathways [J].

Alessi, Dario R. ;

Sakamoto, Kei ;

Bayascas, Jose R. .

ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :137-163

[2] HUMAN MAMMARY SLICES IN ORGAN CULTURE .I. METHOD OF CULTURE + PRELIMINARY OBSERVATIONS ON EFFECT OF INSULIN [J].

BARKER, BE ;

FANGER, H ;

FARNES, P .

EXPERIMENTAL CELL RESEARCH, 1964, 35 (03) :437-&

[3] PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis [J].

Besson, A ;

Robbins, SM ;

Yong, VW .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 263 (03) :605-611

[4] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[5] AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. [J].

Bolster, DR ;

Crozier, SJ ;

Kimball, SR ;

Jefferson, LS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :23977-23980

[6] The Akt pathway in human breast cancer: a tissue-array-based analysis [J].

Bose, S ;

Chandran, S ;

Mirocha, JM ;

Bose, N .

MODERN PATHOLOGY, 2006, 19 (02) :238-245

[7] Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin - Response to Farooki and Schneider [J].

Bowker, Samantha L. ;

Majumdar, Sumit R. ;

Veugelers, Paul ;

Johnson, Jeffrey A. .

DIABETES CARE, 2006, 29 (08) :1990-1991

[8] The involvement of AMP-activated protein kinases in the anti-inflammatory effect of nicotine in vivo and in vitro [J].

Cheng, Pao-Yun ;

Lee, Yen-Mei ;

Law, Kwok-Keung ;

Lin, Chia-Wei ;

Yen, Mao-Hsiunq .

BIOCHEMICAL PHARMACOLOGY, 2007, 74 (12) :1758-1765

[9] Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase [J].

Collins, Qu Fan ;

Liu, Hui-Yu ;

Pi, Jingbo ;

Liu, Zhenqi ;

Quon, Michael J. ;

Cao, Wenhong .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (41) :30143-30149

[10] Clinical development of mammalian target of rapamycin inhibitors [J].

Dancey, JE .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2002, 16 (05) :1101-+

← 1 2 3 4 5 6 7 8 9 →